STXS
Stereotaxis Inc
AMEX: STXS · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$1.85
-6.60% today
Updated 2026-06-03
Market cap
$176.90M
P/E ratio
—
P/S ratio
5.67x
EPS (TTM)
$-0.24
Dividend yield
—
52W range
$2 – $4
Volume
0.4M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
3.3
Growth
D6.0
Quality
B2.0
Profitability
F7.0
Valuation
B+4/9
Piotroski F-Score
Moderate
-15.8
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$4.13
+122.97%
12-Month target
—
—
Intrinsic (DCF)
$3.28
Margin of safety
+38.11%
2 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ 38.11% below intrinsic value
+ Debt/equity 0.27x — low leverage
Risks
- Altman Z -15.81 — distress zone
- Thin margins at -69.50%
- Negative free cash flow $-3.52M
- Revenue declining -15.80% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $28.15M | $26.77M | $26.92M | $32.38M | $31.20M |
| Net income | $-19.15M | $-20.71M | $-24.05M | $-21.64M | $-5.86M |
| EPS | — | — | — | — | $-0.24 |
| Free cash flow | $-10.79M | $-9.51M | $-8.53M | $-13.78M | $-3.52M |
| Profit margin | -68.04% | -77.37% | -89.33% | -66.85% | -69.50% |
Peer comparison
Smart narrative
Stereotaxis Inc trades at $1.85. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -15.81, it sits in the distress. TTM revenue stands at $31.20M. with profit margins at -69.50%. Our DCF model estimates intrinsic value at $3.28.
Frequently asked questions
What is Stereotaxis Inc's stock price?
Stereotaxis Inc (STXS) trades at $1.85, on a P/S of 5.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Stereotaxis Inc overvalued?
Stereotaxis Inc carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $3.28 versus the $1.85 price, a 38.1% margin of safety on a cash flow basis.
What is the price target of Stereotaxis Inc (STXS)?
The 12-month analyst consensus target is $4.13, about 123.0% above the current $1.85. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Stereotaxis Inc (STXS)?
Our DCF model estimates intrinsic value at $3.28, a +38.1% margin of safety versus today's $1.85. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Stereotaxis Inc's revenue?
Stereotaxis Inc's trailing twelve-month revenue is $31.20M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Stereotaxis Inc's Altman Z-Score is -15.81, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeAMEX
CurrencyUSD
Quick metrics
P/S ratio5.67x
ROE-156.10%
Beta1.33
50D MA$1.90
200D MA$2.37
Shares out0.10B
Float0.07B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—